Prospectus lodged in preparation for share offer to Existing Shareholders
17 May 2021
Dear Shareholder,
QBiotics is pleased to advise that it has lodged a Prospectus with the Australian corporate regulator, the Australian Securities and Investments Commission (ASIC), on 17 May 2021. The Prospectus is an offer for 11,111,111 fully paid ordinary shares at $0.90 to raise $10 million, with a minimum raising of $5 million and a provision of oversubscriptions of up to $2.5 million, from Existing Shareholders (the Offer). The Prospectus is subject to an exposure period of seven days from the date of lodgement of the Prospectus with ASIC, or such other period (not exceeding 14 days) as ASIC may require. QBiotics will not be accepting investment applications during the Exposure Period. Application forms for the Offer will not accompany the Prospectus or be available during the Exposure Period.
Existing Shareholders (being holders of shares in QBiotics as at 5pm on 17 May 2021) will be invited to participate in the Offer electronically via an email from Link Market Services, our share registry (or by letter depending on which communication preference you selected for your shareholding with Link Market Services). The communication will include instructions on how to access a copy of the Prospectus and a personalised Application Form, should you wish to participate in the Offer.
The Prospectus together with the Application Form will be made available via QBiotics’ website and email communication after the Exposure Period. If you wish to apply for Shares under the Offer, the preferred method will be via QBiotics’ website atqbiotics.com/prospectus.
Key Dates for the Offer
• Opening Date for Applications (8:30am) 25 May 2021 1 • Closing Date for Applications (5:00pm) 21 June 2021 2 • Issue and allotment of Shares (completion of Offer) 25 June 2021 3 • Expected dispatch of Holding Statements 30 June 2021 If you have any questions in relation to the Offer please refer to the Frequently Asked Questions (FAQ) atqbiotics.com/prospectus. If, after reviewing the FAQ, you have any additional questions, please contact QBiotics Group by phoning (07) 3870 8933 or emailing[email protected].
In the meantime, and for the protection of all shareholders, the Company has halted the Off Market transfers of shares during the Exposure Period, to ensure all investors can be fully informed.
Yours sincerely,
Dr Victoria Gordon
Chief Executive Officer & Managing Director
QBiotics Group Limited
